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This study explored the neurocognitive effects of 4 weeks daily supplementation with
a multi-vitamin and -mineral combination (MVM) in healthy adults (aged 18–40 years).
Using a randomized, double-blind, placebo-controlled design, participants underwent
assessments of brain activity using functional Magnetic Resonance Imaging (fMRI;
n = 32, 16 females) and Steady-State Visual Evoked Potential recordings (SSVEP;
n = 39, 20 females) during working memory and continuous performance tasks at
baseline and following 4 weeks of active MVM treatment or placebo. There were several
treatment-related effects suggestive of changes in functional brain activity associated
with MVM administration. SSVEP data showed latency reductions across centro-parietal
regions during the encoding period of a spatial working memory task following 4 weeks
of active MVM treatment. Complementary results were observed with the fMRI data,
in which a subset of those completing fMRI assessment after SSVEP assessment
(n = 16) demonstrated increased BOLD response during completion of the Rapid
Visual Information Processing task (RVIP) within regions of interest including bilateral
parietal lobes. No treatment-related changes in fMRI data were observed in those
who had not first undergone SSVEP assessment, suggesting these results may be
most evident under conditions of fatigue. Performance on the working memory and
continuous performance tasks did not significantly differ between treatment groups at
follow-up. In addition, within the fatigued fMRI sample, increased RVIP BOLD response
was correlated with the change in number of target detections as part of the RVIP task.
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This study provides preliminary evidence of changes in functional brain activity during
working memory associated with 4 weeks of daily treatment with a multi-vitamin and
-mineral combination in healthy adults, using two distinct but complementary measures
of functional brain activity.
Keywords: multi-vitamin, nutrient, functional magnetic resonance imaging (fMRI), steady-state visual evoked
potentials, working memory
INTRODUCTION
Micronutrients, such as B vitamins and minerals, are critical
components of healthy physiological functioning, yet humans
are dependent on dietary sources in maintaining an adequate
supply. B vitamins are a group of water soluble organic molecules
which act as cofactors in a multitude of cellular processes.
These micronutrients are implicated in catabolic reactions which
support energy metabolism (Depeint et al., 2006; Huskisson
et al., 2007), in addition to anabolic pathways which drive
synthesis of DNA/RNA, antioxidants and neurotransmitters,
whilst also reducing homocysteine to methionine through
roles in one carbon transfer cycles (for a detailed review, see
Kennedy, 2016). While a healthy diet may be sufficient to
maintain adequate supplies of these essential micronutrients,
modern Western dietary patterns may lead to a significant
proportion of the population not meeting recommendations for
a range of micronutrients, including B vitamins (Troesch et al.,
2012).
Looking beyond the prevention of physical illness related
to deficiency in specific B vitamins, there is very little data
exploring optimal micronutrient levels (Neufeld and Cameron,
2012; Kennedy, 2016). Recent work investigating micronutrient
supplementation with a multi-vitamin/mineral preparation
(MVM) in healthy individuals provides support for a distinction
between optimal and sub-optimal micronutrient status (Pietrzik,
1985; Fletcher and Fairfield, 2002) in the absence of a clinical
deficiency. For example, clinical trials investigating the effects of
MVM in healthy adults have generally observed a positive impact
on mood, with meta-analysis indicating significant benefits to
subjective stress, sub-clinical psychiatric symptoms and a range
of everyday mood dimensions (Long and Benton, 2013). Indeed,
mood outcomes were assessed as part of the trial which generated
the functional brain activity assessments described herein, also
showing significant positive effects for aspects of everyday mood
(White et al., 2015).
Given the prominent role of B vitamins in cellular functions
which support brain function, it follows that manipulations of
micronutrients such as B vitamins via MVM supplementation
may impact neurocognitive function. Trials investigating
potential effects of MVM supplementation on cognitive
performance amongst healthy adults have not provided a wholly
consistent picture, partially driven by insufficient research
(Grima et al., 2012). The potential for enhancing cognitive
function amongst healthy adult males was studied by Kennedy
et al. (2010). Serial subtraction task performance completed
as part of a cognitive demand battery was improved following
28-days MVM supplementation. In another study, females aged
25–50 years demonstrated significant cognitive performance
benefits after 63 days of MVM supplementation using a multi-
tasking assessment (Haskell et al., 2010). In contrast, the largest
MVM supplementation trial to date investigating cognitive
changes found no evidence supporting a positive effect of such
treatment in a sample of male physicians aged 65 or older over
a mean follow-up intervention duration of 8.5 years (Grodstein
et al., 2013). These studies not only highlight the variability in
findings when considering possible cognitive function benefits
associated with MVM supplementation in healthy adults,
but also the differences in micronutrient doses and duration
of the MVM treatment, the treatment populations, and the
methods for assessing cognitive performance (for example,
Grodstein et al., 2013 assessed cognitive function by telephone
interview).
Recently, a parallel line of inquiry has explored potential
physiological changes associated with MVM supplementation.
Amongst obese females aged 18–55, daily MVM supplementation
with a preparation containing a large number of minerals
in addition to vitamins over 26 weeks led to an increase in
resting energy expenditure, along with reductions in fat mass,
body weight, and cholesterol (Li et al., 2010). Increased energy
expenditure was again observed in a sample of healthy females
aged 25–49 after MVM supplementation, in this case during
cognitive task performance (Kennedy et al., 2016). Exploring
both acute and acute-on-chronic effects of two MVM treatments,
one higher dose and one lower dose with added Coenzyme Q10,
Kennedy et al. (2016) reported this increase in energy expenditure
during cognitive task performance after both the single acute
dose and in a dose-dependent manner following 56 days of
supplementation. The study also explored brain hemodynamic
changes during completion of the cognitive task battery using
functional near infrared spectroscopy (fNIRS), which revealed
increased cerebral blood flow to prefrontal sites at the first acute
assessment only with the lower MVM dose with Coenzyme
Q10 and similar, albeit non-significant, trends in the high dose
MVM treatment group. These hemodynamic changes were not
accompanied by changes in cognitive function.
Functional Magnetic Resonance Imaging (fMRI) shares some
of the properties of fNIRS but allows far better spatial
resolution. Work from our laboratory has provided preliminary
evidence of neurophysiological changes associated with MVM
supplementation, exploring both acute doses and longer term
supplementation using fMRI and Steady State Visual Evoked
Potentials (SSVEP) – an electrophysiological technique with high
temporal resolution (see below). In a pilot investigation of the
acute effects of two MVM treatments, with or without guaraná,
fMRI during completion of Rapid Visual Information Processing
(RVIP) and Inspection Time tasks revealed increased blood
oxygen level dependent (BOLD) response to active tasks for both
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MVM treatments compared to placebo (Scholey et al., 2013). This
study also reported cognitive performance and mood benefits
restricted to the MVM plus guaraná treatment.
Changes in functional brain activity have been reported
for both acute and chronic MVM supplementation using
SSVEP methodology. Before proceeding with the outcomes
of this work, a brief introduction to the SSVEP technique
is provided. The SSVEP has found applications in the study
of basic visual processes and perception, brain-computer
interfaces and higher order cognitive functions (for reviews,
see Vialatte et al., 2010; Norcia et al., 2015). One SSVEP
method for probing higher cognitive functions, referred to
as Steady State Topography (Silberstein et al., 1990), explores
SSVEP responses to a task-irrelevant diffuse 13 Hz sinusoidal
flicker superimposed onto the visual field during cognitive
task engagement. SSVEP amplitude reflects summed activity
of pyramidal cells firing synchronously with the 13 Hz flicker,
whilst SSVEP phase reflects latency differences between the
visual flicker and the SSVEP response. This phase difference
is argued to reflect cortico-cortical loop transmission time,
which is linked with ongoing excitatory and inhibitory processes
in the underlying cortical regions such that an increase
in excitatory processes will manifest as an SSVEP phase
advance (or reduced latency; Silberstein et al., 1995, 2000).
Using this Steady State Topography method, fluctuations
in SSVEP amplitude and phase have been linked with a
range of cognitive processes (Silberstein et al., 2001; Kemp
et al., 2002; Ellis et al., 2006), neurophysiological changes
in clinical populations (Silberstein et al., 1998, 2000), and
also to probe the neurocognitive effects of a number of
psychopharmacological and nutritional manipulations (Kemp
et al., 2004; Silberstein et al., 2011; Camfield et al., 2012),
including MVM supplementation.
The pilot fMRI findings of Scholey et al. (2013) studying
acute effects of MVM administration were extended using
SSVEP recordings during completion of the A-X Continuous
Performance Task (A-X CPT; White et al., 2016). This study
found distinct changes in SSVEP response during the A-X
CPT associated with MVM supplementation containing higher
B vitamin and mineral doses and a second MVM with lower
micronutrient doses but additional guaraná. After the high
dose MVM treatment, SSVEP amplitude reduction and phase
advance were observed in frontal electrode sites during the
period between the probe and target stimuli, a pattern which
was correlated with better task performance. In contrast, the low
dose MVM with guaraná showed little evidence of any phasic
task-related SSVEP fluctuations, instead causing a generalized
shift toward greater phase advance, with a diffuse topographic
pattern, consistent with the general excitatory actions of the
caffeine content in the treatment. Macpherson et al. (2012)
explored changes in functional brain activity related to MVM
supplementation over 16 weeks in females aged 64–79 using
SSVEP recordings. This trial tested the effects of supplementation
with an MVM preparation, which also contained 19 plant extracts
and three probiotics, with changes in SSVEP studied during
completion of a spatial working memory task. The study observed
greater SSVEP phase lag (increased latency) during the retrieval
component of the spatial working memory task, a pattern of
change which was correlated with improved task performance
post-treatment.
To summarize, micronutrients are essential cofactors in
a host of cellular processes critical to healthy physiological
and neurocognitive functioning, with an increasing effort to
understand whether intake other than in the context of
avoiding clinical deficiency may enhance function in otherwise
healthy individuals. Where studies have considered behavioral
outcomes of MVM interventions in healthy adults, results
indicate potential benefits to mood, with support, though less
consistent, for cognitive performance benefits. There is also
evidence to suggest MVM supplementation may influence energy
metabolism, and possibly more specific neurophysiological
functions. In studies assessing task-related SSVEP changes
following MVM administration, the technique appears sensitive
to potential changes in functional brain activity related to MVM
supplementation, whilst the pilot data using fMRI methods
warrant further investigation. To this end, the current study
aimed to utilize these complementary methods, fMRI and SSVEP,
to assess functional brain activity in order to explore any potential
relationship between MVM supplementation and brain function
in healthy adults.
MATERIALS AND METHODS
We studied functional imaging outcomes, employing a
randomized, double-blind, placebo controlled design to
investigate the effects of 4 weeks daily supplementation
with a MVM combination. The intervention consisted of a
micronutrient preparation containing all eight B vitamins, in
addition to Vitamin C and the minerals calcium, magnesium
and zinc (further detailed below). The overall trial methods
and outcomes relating to mood and blood biomarkers have
been published elsewhere (White et al., 2015). The study
was approved by the Swinburne University Human Research
Ethics Committee (Ref SUHREC 2012/164) and was registered
with the Australian New Zealand Clinical Trials Registry
(ACTRN12612001043820).
Participants
The study enrolled 58 healthy adult participants aged between
18 and 40 years of age (Mean age = 25.82 years, SD = 4.87),
who were recruited from the local community via local
advertisements. Participants were free of psychiatric or serious
physical illnesses and had not taken medication (with the
exception of the contraceptive pill or routine medications
for benign conditions), herbal extracts, vitamin supplements
or illicit drugs within 4 weeks prior to enrolment and
for study duration. These participants completed one of
three functional brain imaging assessment streams (further
detailed in Supplementary Figure 3): both SSVEP and fMRI
(n = 16, eight females, one additional participant withdrew
consent prior to follow-up assessment), SSVEP assessment alone
(n = 23, 12 female), and fMRI assessment alone (n = 16,
eight females, with two additional participants who withdrew
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consent prior to follow-up assessment). Those who completed
both SSVEP and fMRI assessment did so on the same
testing day, with SSVEP recordings undertaken prior to fMRI
assessment.
Procedure
Participants attended an initial screening and familiarization
visit, followed by baseline and post-treatment assessment sessions
conducted 4 weeks apart. Participants were given an opportunity
to practice each of the cognitive tasks at the screening
visit, with SSVEP and fMRI assessment of functional brain
activity performed at baseline and 4 weeks post-treatment.
Randomization was conducted by a disinterested third party,
with stratified randomization used to balance gender within each
functional imaging assessment stream. The active and placebo
treatments were effervescent tablets matched for color and flavor,
prepared by Bayer AG (Basel, Switzerland). The active treatment,
containing high doses of B vitamins, in addition to zinc, calcium,
magnesium and vitamin C, is commercially available as Berocca R©
Performance (detailed in Table 1 below). Participants were
instructed to take one tablet daily with breakfast, dissolved in
at least 200 mL of water. Participants returned after 4 weeks of
supplementation having not taken a treatment on the day of their
return visit. Compliance was determined by a count of returned
treatments, whilst analysis of circulating levels of vitamin B6, Red
Cell Folate and B12 showed increases post-treatment in the active
treatment group, with significant reductions in homocysteine,
confirming compliance and absorption (for details, see White
et al., 2015).
TABLE 1 | Micronutrient doses of the active MVM treatment.
Nutrient Amount (mg) % RDA/RDI
Males Females
Vitamin C 500 556 (1111) 667 (1111)
Thiamine
monophosphoric acid
ester chloride
18.54 1545 1685
Riboflavin (vitamin B2) 15 1154 1364
Nicotinamide
(B3/niacin)
50 313 357
Vitamin B5 23 460∗ (383∗) 460∗ (575∗)
Vitamin B6 10 769 769
Vitamin B12 0.01 417 417
Folic Acid (Vitamin B9) 0.4 100 100
Biotin (Vitamin B7) 0.15 500∗ 500∗ (600∗)
Calcium 100 10 10
Magnesium 100 25 32
Zinc 10 91 (71) 125
% RDA (RDI) is the percentage for each micronutrient of Recommended Dietary
Allowances derived from Dietary References Intakes of the Institute of Medicine,
National Academy of Sciences (US) and Recommended Daily Intake from the
Nutrient Reference Values of the National Health and Medical Research Council
(Australia) for healthy adults in the age range 19–30. Where a second number
appears in brackets, the US and Australian reference values disagree, in which
case US RDA’s are given first with Australian RDI’s in brackets. ∗ Indicates the use
of ‘Adequate Intakes’ where RDA/RDI could not be determined.
Functional MRI Acquisition
MRI scanning used a Siemens Tim Trio 3T MRI scanner
equipped with a 32-channel head coil at Swinburne University
of Technology, Melbourne, Australia. Functional MRI data was
acquired during completion of an Inspection Time (IT) task and
the RVIP task. At baseline and post-treatment assessments, the
imaging protocol included a T1-weighted scan (3D MPRAGE;
TR = 1900 ms, TE = 2.52 ms, flip angle = 9◦, Field of
View = 256 mm, 176 slices, 1 mm3 isotropic voxels), in addition
to T2∗-weighted volumes obtained during completion of the two
cognitive tasks using the same EPI acquisition parameters, with
the first three volumes of each task run discarded (TR= 3000 ms,
TE = 30 ms, flip angle = 90◦, Field of View = 192 mm, 46
interleaved slices, 3 mm3 isotropic voxels). Both IT and RVIP
tasks, described below, were variants of previously published task
paradigms presented using Presentation R© software1. Participants
viewed the task stimuli on a monitor through a mirror on the
head coil.
Inspection Time Task Details
The IT task involved presentation of a stimulus with two
vertical lines of varying lengths running perpendicular at
either end of a horizontal line (white stimuli on a black
background). The participant was then required to indicate
which line was perceived as longer (forced choice, with two
alternatives, via button box held in the right hand with an
index finger (left) or middle finger (right) button press). The
duration for which this stimulus remained visible, prior to
the appearance of a mask (500 ms mask duration), varied
from equally represented trials of 40, 60, 80, 100, and 120 ms
(Waiter et al., 2008). Trials were preceded by a 600 ms
fixation cross, with a variable inter-trial interval (ITI) comprising
each 500 ms increment from 1880 to 3880 ms. Each ITI
preceded the five stimulus durations equally, with 20 trials of
each stimulus duration presented in a pseudorandom order
per run of the task. Two 426-second runs (142 functional
volumes), each of 100 trials, were conducted at each assessment
visit.
Rapid Visual Information Processing Task Details
The RVIP task implemented was identical to that described in
Neale et al. (2015). Briefly, single digits (white stimuli on a
black background) were presented at a rate of 100 per minute,
with the active task variant requiring participants to respond
upon presentation of three consecutive odd or even digits, and
a control task variant requiring detection of a single target digit
not presented during the active variant (‘0’). Both task variants
contained target sequences at a rate of four per 30 s. The two
task variants alternated in a blocked design, with each 58.5-
second block preceded by a 12-second rest/instruction block,
which cued participants to the upcoming task requirements. Two
runs of the task were completed at each assessment visit, with
each run comprising three blocks of each task variant and seven
rest/instruction blocks for a total of 435 s (145 functional volumes
per run).
1www.neurobs.com
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fMRI Data Processing and Analysis
All pre-processing and participant-level statistical analysis of
fMRI data were performed using SPM8 (Wellcome Trust
Centre for Neuroimaging, London, UK). Data pre-processing
included the following steps: the image time-series were slice-
time corrected referenced to the middle slice, then realigned to
the first volume acquired. The T1 structural image acquired at
the corresponding treatment visit was co-registered to a mean
functional image created during realignment, then normalized to
MNI T1 template released with SPM8. The parameters of this
T1 transformation were subsequently applied to the realigned
functional images. The normalized functional images were then
smoothed with an 8 mm FWHM Gaussian filter.
Participant-level modeling for the IT task explored the
parametric modulation of BOLD signal as a function of
stimulus duration. Correct trial events were modeled as
stick functions convolved with the canonical hemodynamic
response function (HRF) supplied with SPM8. These correct
events were parametrically modulated with a regressor coding
trial presentation duration (longest durations had the highest
numbers) that was orthogonalized to the event regressor; the
parametric modulator expresses how well BOLD fluctuations not
explained by the average response to all stimulus onsets covaries
with stimulus presentation length. Finally, motion correlated
BOLD signal variance was modeled by including the motion
realignment parameters as covariates of no interest.
At the group level of analysis, the parametric modulation
effect showed no statistically significant effects at baseline (see
Supplementary Data Section 2). In the absence of reliable task
effects at baseline, this task was not pursued for potential effects
of treatment.
Participant-level modeling for the RVIP task modeled active
and control variants of the task using separate boxcar functions
defined by the onset and duration of each task block that were
convolved with the canonical HRF, with the motion parameters
included as nuisance regressors. Analysis of treatment effects
on RVIP task-related functional brain activity adopted a region-
of-interest (ROI) approach, deriving functional ROIs from an
independent sample of healthy participants matching eligibility
criteria for the study. The details of the analysis generating the
five ROIs used are described in Supplementary Data Section 1
(see Supplementary Table 1 and Supplementary Figure 1). The
five ROIs identified by this analysis were localized to a left and
right parietal cluster, a left middle frontal cluster, the left insula
and a cluster comprising bilateral supplementary motor areas.
Mean contrast estimates obtained from the active task minus
control task contrast were extracted from the five ROIs, using
the MarsBaR toolbox2 (Brett et al., 2002). Given the demands of
the control task largely match the attentional and sensorimotor
demands of the active variant, this contrast largely isolates
working memory demands required by the active variant of
the task. These mean contrast estimates obtained at the post-
treatment visit formed the input for an analysis of covariance
(ANCOVA) examining the main effect of treatment group as
a between-group factor, with pre-treatment baseline estimates
2http://marsbar.sourceforge.net
included as a covariate using SPSS for Windows (Version 23;
SPSS Inc., Chicago, IL, USA). Comparisons were thresholded for
significance using False Discovery Rate correction with q = 0.1
in order to control for multiple comparisons across the five ROIs
(Benjamini and Hochberg, 1995).
Steady-State Visually Evoked Potential
Recordings
Two cognitive tasks, one continuous performance task and one
spatial working memory task, were completed during recordings
of the SSVEP. Acquisition and pre-processing of the SSVEP
followed an identical procedure to that described in a recent study
exploring the acute effects of MVM administration, both with
and without guaraná (White et al., 2016). Briefly, recordings were
acquired from 60 scalp electrodes, positioned according to the
extended 10-10 system using a Quick-Caps electrode cap and
Synamps2 amplifiers with Scan 4.3 Software (Neuroscan, Inc.,
Abbotsford, VIC, Australia). An electrode positioned between
Cz and Cpz acted as the reference, with the ground electrode
positioned between Fz and Fpz. Recordings were also taken from
left and right mastoids, with data subsequently re-referenced to
linked mastoids off-line. The SSVEP was elicited through goggles
using LED arrays emitting a 13 Hz sinusoidal flicker, which
was superimposed over the visual field with half-silvered mirrors
subtending a horizontal angle of 160◦ and vertical angle of 90◦.
SSVEP Cognitive Tasks: A-X Continuous
Performance Task
The details of the AX-CPT used in the present study are identical
to that described in the previous investigation of the acute
effects of MVM administration (White et al., 2016). The task
presents single letters at a rate of approximately 34 per minute,
and involves two variants: one active task in which participants
respond to a target sequence of ‘X’ preceded by ‘A’ amongst a
pseudo-random sequence of letters, and a control task in which
participants respond to a target letter ‘E’ amongst a predictable
repeated sequence of letters (‘A’ through ‘E’). For both variants
200 stimuli, including 40 target responses, were presented across
two recording runs of approximately 3 min each separated by a
short break.
SSVEP Cognitive Task: Spatial Working Memory
The spatial working memory task adopted for the current study
was based on a delayed match-to-sample paradigm with a history
of use in studying the functional imaging correlates of spatial
working memory (Jonides et al., 1993), which has previously
been used to explore age-related changes in SSVEP response
(Macpherson et al., 2014), in addition to changes associated with
MVM supplementation in healthy older females (Macpherson
et al., 2012). Trials presented either two or three white dots on
a black background for 500 ms (encoding period), followed by
presentation of a fixation cross for 3000 ms (maintenance period),
after which an empty circle appeared for 1800 ms (probe). During
this probe period, participants responded as to whether the
location of the circle enclosed an encoded location of the dot
stimuli, with a right button press indicating a match and a left
button press indicating a new location. The control variant of
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the task matched sensorimotor demands of the task, removing
the working memory load by retaining the dot stimuli on-
screen throughout the duration of each trial, such that the probe
period required a response as to whether the circle stimuli either
surrounded a dot (right button press) or did not enclose a dot (left
button press). Active and control task variants were completed
in separate recording runs, comprising 40 trials separated by a
1000 ms fixation period, half of which presented two dots during
encoding and half three dots. To ensure a sufficient number of
correct trials for analysis, two runs of the active task variant were
completed, resulting in 80 trials for the active task per visit and a
single run of 40 trials for the control variant.
SSVEP Data Processing and Analysis
All aspects of the SSVEP signal processing were identical to that
described in White et al. (2016), with the 13 Hz SSVEP signal
extracted from ongoing recordings using established routines
implemented in in-house software (BrainSci; Silberstein, 1995b)
and statistical analysis and mapping using custom MATLAB
scripts (The Mathworks Inc., Natick, MA, USA). In order to
control for inter-individual differences in SSVEP amplitude and
phase responses, the active task variants of both AX-CPT and
SWM task paradigms were normalized to the corresponding
control task variant at the baseline visit. For the A-X CPT task,
mean SSVEP amplitude and phase were calculated for the 250 ms
period following the cue stimulus (‘A’), the 1500 ms hold period
following, and the 1000 ms from target appearance (‘X’). For the
SWM task, mean SSVEP amplitude and phase were calculated for
the 500 ms encoding period, the 3000 ms maintenance period,
and the 1000 ms from presentation of the probe stimulus. As only
correct trials were included in analyses, one further participant
was excluded from analysis of A-X CPT, due to incorrect task
performance.
Both A-X CPT and SWM tasks were studied across the entire
SSVEP sample at baseline to characterize the SSVEP response to
task completion pre-treatment. For each of the three averaged
task components, this involved direct comparison between the
active and control task variant for both tasks. Subsequently,
potential changes in SSVEP response from baseline to post-
treatment were investigated, contrasting the active task SSVEP
response at each visit for each treatment group separately.
The SSVEP response is studied in terms of amplitude and
phase, necessitating an alternate statistical approach to that
of behavioral and fMRI data. Comparisons were conducted
using Hotelling’s T2, the bivariate analog to a paired T-test,
which tests for differences in the mean vector comprising the
complex numbers quantifying the SSVEP amplitude and phase.
Adjustment for multiple comparisons followed previous research
to use the Steady State Topography method, in which spatial
principal component analysis of SSVEP data indicating five
independent components can account for over 95% of spatial
variance (Silberstein and Cadusch, 1992), thus the alpha level for
SSVEP analysis was adjusted to 1% (adjusted p = 0.05/5). In the
event of significant changes, the association between these SSVEP
changes and behavioral performance changes from baseline
to post-treatment were also explored through correlations in
order to assess any behavioral correlates of these changes (that
is, the difference in SSVEP response pre- to post-treatment
was correlated with the change in performance between these
assessment visits).
Analysis of Behavioral Performance
Behavioral performance on cognitive tasks was measured in
terms of accuracy and mean response time for the active
variant of each of the four cognitive tasks. Task accuracy was
operationalized as the percentage of correct responses for IT and
spatial working memory tasks and the mean number correct
target detections per task run in the case of the RVIP (out of 24
per run) and A-X CP tasks (out of 20 per run). To investigate
potential treatment-related changes in behavioral performance,
task accuracy and response times at the post-treatment visit
formed the input for an analysis of covariance (ANCOVA)
examining the main effect of treatment group as a between-
group factor, with pre-treatment baseline estimates included as
a covariate using SPSS for Windows (Version 23; SPSS Inc.,
Chicago, IL, USA). Criteria for significance across behavioral
outcomes was set to p< 0.05.
Analysis Populations
The analysis population for each outcome required complete
cases (55 of the 58 randomized completed follow-up
assessments), with the following additional criteria for each
type of outcome: (a) behavioral performance data: primary
analysis on complete cases with additional exclusion of outliers
identified during data-screening conducted while blind to
treatment, (b) for fMRI: primary analysis on complete datasets,
with follow-up sensitivity analyses excluding behavioral outliers
identified during blind data-screening, (c) for SSVEP data:
primary analysis was conducted on complete cases with
additional exclusion of datasets with excessive artifact, as defined
by an arbitrary threshold described below, with follow-up
analyses excluding behavioral outliers.
Prior to unblinding, behavioral outcomes were screened for
outliers, in which behavioral performance approximating chance
levels was observed for five participants on the IT task, who
were subsequently excluded from analysis. Poor performance was
also observed for a single participant on the RVIP task, three
participants on the A-X CPT, and a single participant on the
Spatial Working Memory task who were excluded from analysis
of these behavioral outcomes. An additional three participants
were missing behavioral data for the RVIP task due to a technical
fault with the response device in the scanner, and were thus
missing from analysis of behavioral results. Excessive SSVEP
artifact was defined by a circular statistic exceeding 0.2 in
10 or more electrodes for a given task variant (described in
Silberstein, 1995a), calculated for the first 120 s of each task
run. This threshold resulted in the exclusion of three datasets
from the Spatial Working Memory task, and no datasets from
the A-X CPT. As fMRI data was acquired from two cohorts in
which testing procedures differed, these groups were analyzed
separately. As previously reported, assessment of functional
brain activity using SSVEP recordings during A-X CPT and
Spatial Working Memory tasks significantly decreased subjective
ratings of mental stamina, concentration and alertness, while
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significantly increasing mental fatigue (further detailed in White
et al., 2016), further emphasizing the need to consider the cohort
in which fMRI was completed after SSVEP assessment separately.
RESULTS
Behavioral Performance
Behavioral performance on the cognitive tasks completed during
monitoring of functional brain activity using SSVEP and fMRI
methods did not significantly differ between treatment groups
post-treatment, when controlling for baseline scores. Mean
performance on MRI-based tasks tended to be poorer at both
visits in the fatigued sample, though the two testing cohorts did
not significantly differ. These results are summarized in Table 2
below.
fMRI
Task Effects
Whole brain voxel-wise patterns of task-related activity were
studied at baseline, in order to confirm that performance of
the RVIP and IT tasks elicited activity consistent with previous
research, also justifying the regions of interest identified from
the independent sample for use in exploring treatment-related
effects during RVIP task performance. The IT task failed to show
reliable task effects, when exploring parametric modulation of the
BOLD signal by stimulus presentation length (cf. Deary et al.,
2004; Waiter et al., 2008), and as such was not pursued further
for effects of treatment. The RVIP task showed results consistent
with previous functional imaging studies of this task (Coull et al.,
1996; Lawrence et al., 2003; Neale et al., 2015) and the ROIs
defined from the independent sample, including large regions
of bilateral parietal and frontal cortex. The outcomes of these
analyses are further detailed in Supplementary Data Section 2 (see
Supplementary Table 2 and Supplementary Figure 2).
RVIP Post-treatment Effects
Amongst fatigued participants, who underwent SSVEP
assessment prior to fMRI, mean contrast estimates derived
from subtracting the control RVIP task variant from the active
RVIP task variant were significantly higher post-treatment in the
MVM treatment group compared to placebo, when controlling
for baseline. This effect survived FDR correction across three
ROIs: bilateral parietal lobe ROIs and the supplementary motor
area ROI. Repeating this analysis with the exclusion of a single
poor-performing participant (placebo group) showed the same
TABLE 2 | Behavioral performance on cognitive tasks.
Cohort Task/outcome Treatment M (adj) SE F p
SSVEP A-X CPT – Hits (/20) Plac (n = 18) 18.72 0.41 0.16 0.691
MVM (n = 18) 18.95 0.41
A-X CPT – RT Plac (n = 18) 357 10.54 3.07 0.089
MVM (n = 18) 331 10.54
Spatial Working Memory – Accuracy Plac (n = 20) 76.62 1.57 0.01 0.924
MVM (n = 18) 76.40 1.65
Spatial Working Memory – RT Plac (n = 20) 631 23 1.26 0.269
MVM (n = 18) 669 24
fMRI: Fatigued IT – Accuracy Plac (n = 5) 92.56 2.97 2.25 0.168
MVM (n = 7) 86.17 2.41
IT – RT Plac (n = 5) 471 35 0.40 0.545
MVM (n = 7) 442 29
RVIP – Hits (/24) Plac (n = 6) 14.43 1.60 0.82 0.388
MVM (n = 6) 16.49 1.60
RVIP – RT Plac (n = 6) 487 24 0.12 0.735
MVM (n = 6) 476 24
fMRI: Non-fatigued IT – Accuracy Plac (n = 6) 94.97 0.92 0.41 0.537
MVM (n = 7) 94.17 0.85
IT – RT Plac (n = 6) 452 34 0.23 0.644
MVM (n = 7) 430 31
RVIP – Hits (/24) Plac (n = 8) 19.29 0.66 1.28 0.278
MVM (n = 8) 18.21 0.66
RVIP – RT Plac (n = 8) 464 20 0.20 0.663
MVM (n = 8) 477 20
Mean (and Standard Error) accuracy and response time for cognitive tasks completed during functional brain activity assessment at post-treatment assessment, adjusted
for baseline performance. F- and p-values correspond to ANCOVA model testing main effect of treatment group on post-treatment performance, controlling for baseline
performance. M (adj), Baseline adjusted estimated marginal means of post-treatment performance; RT, response time; Hits, mean target detections; MVM, multi-vitamin
and mineral treatment group; Plac, Placebo; ANCOVA results reported for main effect of treatment group.
Frontiers in Aging Neuroscience | www.frontiersin.org 7 December 2016 | Volume 8 | Article 288
fnagi-08-00288 December 1, 2016 Time: 17:31 # 8
White et al. Micronutrients and Brain Activity
pattern of results, with left parietal and SMA ROIs surviving
FDR correction. In contrast, no significant differences between
treatment groups were observed amongst the non-fatigued
cohort of participants. These outcomes are detailed in Table 3,
while Figure 1 depicts mean contrast estimates for fatigued and
non-fatigued groups pre- and post-treatment within the three
ROIs for which significant differences between treatment groups
were observed.
Within the fatigued sample, the change in RVIP task-related
activity from baseline to post-treatment was pursued in order to
assess the relationship with changes in behavioral performance.
Positive correlations were observed between the change in RVIP
task performance from baseline to post-treatment, as indexed by
total number of correct target detections, and change in RVIP
contrast estimate from baseline to post-treatment in the Left
Parietal (rs = 0.681, p = 0.015), Right Parietal (rs = 0.628,
p = 0.029) and SMA (rs = 0.491, p = 0.105) regions of interest.
Increased functional brain activity during RVIP task completion
at follow-up was found to be associated with more improved
performance amongst fatigued participants. Scatterplots of the
association between change in functional activity and behavioral
performance are shown in Figure 2 for the two parietal regions
of interest, in which significant (p < 0.05) correlations were
observed.
SSVEP
A-X CPT: Baseline SSVEP Task Effects
SSVEP amplitude and phase differences between active and
control task variants across the sample at baseline are shown in
Figure 3. Consistent with previous research, reduced amplitude
was observed across the three periods of the task, in prefrontal
and posterior sites during the Cue period, continuing across
fronto-central and posterior sites during Hold and Target
components of the task. SSVEP phase demonstrated modest
frontal advance during the Cue period, whilst a right posterior
phase lag during this period extended more broadly across Hold
and Target periods. The prefrontal phase advance previously
reported in combination with amplitude reduction during Hold
and Target task components (cf. Silberstein et al., 1998; Silberstein
et al., 2000; White et al., 2016) was less apparent in the current
sample.
A-X CPT: Treatment Group SSVEP Analysis
Changes in SSVEP response from baseline to post-treatment
were explored for placebo and active MVM treatment groups
separately. For the placebo treatment group, there were no
significant differences in SSVEP response to the A-X CPT
between baseline and post-treatment visits across the three
task components (shown in Figure 4). Trends (p < 0.05,
not reaching threshold) were observed for a small number
of parieto-occipital electrodes where amplitude reduction and
phase advance across the three task components were observed
at follow-up assessment. The active MVM treatment group
showed significant amplitude reduction post-treatment in a
single occipital site during the Hold period (shown in Figure 5).
In addition, a cluster of frontal electrodes showed a trend
(p< 0.05) toward decreased amplitude and phase advance. While
this pattern of frontal phase advance and amplitude reduction did
TABLE 3 | Mean RVIP task-related contrast estimates post-treatment from the five regions of interest for each treatment group, adjusted for baseline, in
both fatigued (n = 16) and non-fatigued cohorts (n = 16).
ROI Treatment M (adj) SE F p η2p
Fatigued Left Parietal Plac 1.06 0.23 7.95 0.015 ∗ 0.379
MVM 1.96 0.23
Right Parietal Plac 1.25 0.21 4.84 0.047 ∗ 0.271
MVM 1.89 0.21
Left Frontal Plac 2.08 0.54 2.17 0.164
MVM 3.21 0.54
Supplementary Motor Area Plac 1.40 0.29 7.35 0.018 ∗ 0.361
MVM 2.50 0.29
Left Insula Plac 1.32 0.32 0.39 0.543
MVM 1.62 0.32
Non-fatigued Left Parietal Plac 1.88 0.30 0.10 0.760
MVM 1.75 0.30
Right Parietal Plac 1.69 0.26 0.13 0.726
MVM 1.56 0.26
Left Frontal Plac 2.90 0.52 0.06 0.808
MVM 2.72 0.52
Supplementary Motor Area Plac 2.39 0.44 1.22 0.290
MVM 1.70 0.44
Left Insula Plac 1.63 0.40 0.21 0.655
MVM 1.37 0.40
ROI, region of interest; M (adj), baseline adjusted estimated marginal means; Plac, placebo group; MVM, multi-vitamin and mineral group; ANCOVA results reported for
main effect of treatment group; ∗significant after FDR thresholding.
Frontiers in Aging Neuroscience | www.frontiersin.org 8 December 2016 | Volume 8 | Article 288
fnagi-08-00288 December 1, 2016 Time: 17:31 # 9
White et al. Micronutrients and Brain Activity
FIGURE 1 | Mean RVIP task contrast estimates extracted at baseline and post-treatment for fatigued (left) and non-fatigued (right) cohorts for (A) Left
Parietal, (B) Right Parietal, and (C) SMA regions of interest, where significantly greater task-related activity was observed in active treatment group post-treatment
within the fatigued cohort. Error bars ±1 SE.
not reach significance when adjusting for multiple comparisons,
this effect is consistent, both in terms of task component and
electrode locations, to previously reported changes in SSVEP
response during completion of the A-X CPT after an acute dose
of the same MVM intervention (White et al., 2016). Patterns
of change and statistical significance were unchanged when
sensitivity analyses were pursued, excluding behavioral outliers.
There were no significant correlations between the change in
behavioral performance from baseline to post-treatment and
these changes in SSVEP response during A-X CPT.
Spatial Working Memory: Baseline SSVEP Task
Effects
The SSVEP response to the active task variant contrasted
with the control variant showed a pattern of reduced SSVEP
amplitude and phase advance in prefrontal electrodes during
encoding, followed by posterior phase advance during the hold
period, as shown in Figure 6. No significant differences were
observed in the retrieval segment, in the first 1000 ms following
presentation of the probe, between the control and active task
variants.
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FIGURE 2 | Scatterplots of association between change in RVIP contrast estimate and change in behavioral performance from baseline to
post-treatment within the fatigued cohort for (A) Left Parietal and (B) Right Parietal regions of interest.
Spatial Working Memory: Treatment Group SSVEP
Analysis
Contrasting SSVEP responses post-treatment with baseline
activity during the Spatial Working Memory task showed
no significant changes in the placebo treatment group, but
evidence of significant changes post-treatment in the active MVM
treatment group. In the placebo group, shown in Figure 7, trends
toward greater phase lag (increased latency) were observed in
the three pre-frontal electrodes during the encoding period, in
addition to a left frontal pattern of phase lag and amplitude
reduction in the maintenance period, though neither reached
significance when adjusting for multiple comparisons. The active
MVM treatment group showed centro-parietal SSVEP phase
advance (reduced latency) during the encoding segment of the
Spatial Working Memory task (shown in Figure 8), reaching
criteria for significance in two central electrodes when adjusting
for multiple comparisons. This pattern of SSVEP phase advance
in centro-parietal regions persisted into the maintenance period,
though it did not reach criteria for significance in this time
window. This change in SSVEP phase response in central
electrodes during encoding was not correlated with the change in
behavioral performance from baseline to post-treatment within
the active MVM treatment group.
DISCUSSION
This study investigated the effects of 4 weeks daily treatment
with a MVM preparation on functional brain activity, as assessed
by complementary hemodynamic and electrophysiological
methods. Both fMRI and SSVEP modalities revealed changes
in functional brain activity following treatment with the active
MVM treatment, with converging patterns of activity consistent
with greater activity in overlapping centro-parietal regions
during working memory task performance. Within the fMRI
data, this increase in task-related BOLD response was correlated
with improved behavioral performance, however, these fMRI
findings were only apparent amongst the fatigued cohort
of participants who had first undergone SSVEP assessment.
The active MVM treatment was also associated with greater
posterior SSVEP amplitude reductions post-treatment during
the period between the cue and target stimuli of the A-X CPT,
as well as a trend toward SSVEP amplitude reductions and
phase advance across frontal regions. MVM treatment was not
associated with significant changes in behavioral performance
on the cognitive tasks completed during monitoring of
functional brain activity. Thus, outcomes of this trial point
to changes in functional brain activity associated with MVM
treatment over 4 weeks. These findings, however, must be
considered in light of the limited evidence of behavioral
change in cognitive task performance (while acknowledging
that the cognitive evaluation were primarily designed as
activation tasks rather than to capture any treatment-related
effects).
Changes in Functional Brain Activity
during Working Memory
Changes in functional brain activity reflecting greater activity in
centro-parietal regions in the MVM arm were observed during
working memory tasks using both imaging methodologies. As
part of the SSVEP changes, the active MVM treatment group
showed SSVEP phase advance (reduced latency) across centro-
parietal regions. The temporal resolution of the SSVEP method
allows isolation of sub-components of the working memory task,
which indicated this increase was maximal during the encoding
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FIGURE 3 | A-X CPT SSVEP amplitude and phase differences, contrasted with the control task, at the baseline assessment across the sample.
Columns show topographic maps of SSVEP amplitude (top) and phase (as latency, middle), with Hotelling’s T2 corresponding to the contrast of active and control
task variants for Cue (Left), Hold (Middle) and Target (Right) task segments.
period of the task. This pattern was broadly consistent with
the effects observed in the fatigued cohort during the RVIP
task using fMRI, where bilateral parietal and supplementary
motor area regions of interest showed greater task-related BOLD
in the MVM group. While these two tasks represent distinct
working memory paradigms (delayed matching-to-sample versus
continuous performance), the probing of treatment effects within
the fMRI data used contrast images derived from the active task
minus the control task variant. This allows relatively complete
isolation of working memory demands during the active task.
Thus these two patterns of change provide converging evidence
of increased functional brain activity associated with MVM
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FIGURE 4 | A-X CPT SSVEP amplitude and phase changes from baseline to post-treatment in the placebo group. Columns show topographic maps of
SSVEP amplitude (top) and phase (as latency, middle), with Hotelling’s T2 corresponding to the contrast of active and control task variants for Cue (Left), Hold
(Middle), and Target (Right) task segments.
supplementation during actively engaged working memory
processes.
Given the preliminary nature of this investigation, the source
of disparate findings relating to potential treatment-related
changes in task-related BOLD response between the fatigued
and non-fatigued fMRI cohorts remains unclear. One possible
explanation is that, amongst healthy adults, the neurocognitive
benefits of this supplementation are more apparent under
conditions of greater cognitive demand. Supporting such a
possibility, previous work exploring cognitive changes following
4 weeks of MVM supplementation in healthy adult males
demonstrated benefits, both in terms of cognitive performance
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FIGURE 5 | A-X CPT SSVEP amplitude and phase changes from baseline to post-treatment in the active MVM treatment group. Columns show
topographic maps of SSVEP amplitude (top) and phase (as latency, middle), with Hotelling’s T2 corresponding to the contrast of active and control task variants for
Cue (Left), Hold (Middle) and Target (Right) task segments.
and subjective ratings of fatigue, during completion of a 1 h
cognitive demand battery (Kennedy et al., 2010). Given the
relatively insensitive approach to detecting BOLD changes
adopted in the current investigation (extracting mean task-
related estimates of activity from broad regions of interest),
it may be that robust differences are only apparent when
placing the individual under greater demand. Further replication
and detailed investigation of this effect is required to better
understand these effects.
The observed changes in SSVEP response during completion
of the spatial working memory task associated with MVM
supplementation are in contrast with those of Macpherson et al.
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FIGURE 6 | Spatial Working Memory SSVEP amplitude and phase differences, contrasted with the control task, at the baseline assessment across
the sample. Columns show topographic maps of SSVEP amplitude (top) and phase (as latency, middle), with Hotelling’s T2 corresponding to the contrast of active
and control task variants for Encoding (Left), Maintenance (Middle), and Retrieval (Right) task segments.
(2012), where latency increases (phase lag) were observed in
elderly women after MVM supplementation during the retrieval
period of the same task used herein. However, the previous
trial by Macpherson et al. (2012) studied an intervention which
contained 19 plant extracts and three probiotics in addition
to micronutrients. For example, the intervention described by
Macpherson et al. (2012) included a relatively large dose of
Ginkgo Biloba (1000 mg), an extract which has been shown to
exert a range of complex actions in vitro as a GABA, glycine and
5HT receptor antagonist (Huang et al., 2003; Hawthorne et al.,
2006; Thompson et al., 2011). As such, the disparate findings
of Macpherson et al. (2012) and those of the present report, in
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FIGURE 7 | Spatial Working Memory SSVEP amplitude and phase changes from baseline to post-treatment in the placebo treatment group. Columns
show topographic maps of SSVEP amplitude (top) and phase (as latency, middle), with Hotelling’s T2 corresponding to the contrast of active and control task
variants for Encoding (Left), Maintenance (Middle) and Retrieval (Right) task segments.
which treatment involved only B vitamins, vitamin C, and three
minerals, are likely driven by the variability in the treatment
constituents.
Changes in Functional Brain Activity
during Cued Attention
The active MVM treatment group also showed greater posterior
SSVEP amplitude reductions post-treatment during the period
between the cue and target stimuli of the A-X task, as well as
a trend of reduced amplitude and phase advance across frontal
regions. Previous studies to explore SSVEP correlates of attention
showed decreased amplitude in posterior electrodes where task
demands were increased during visual vigilance tasks (Silberstein
et al., 1990), which are consistent with the pattern of results
observed in the present study across all participants at baseline.
This reduced SSVEP amplitude during attention tasks which
require ongoing processing of visual stimuli is thought to reflect
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FIGURE 8 | Spatial Working Memory SSVEP amplitude and phase changes from baseline to post-treatment in the active MVM treatment group.
Columns show topographic maps of SSVEP amplitude (top) and phase (as latency, middle), with Hotelling’s T2 corresponding to the contrast of active and control
task variants for Encoding (Left), Maintenance (Middle) and Retrieval (Right) task segments.
an inhibition of the re-entrant cortico-cortical loop transmission
efficiency through cortical layer I, as the sensory inputs to layer
IV are enhanced with visual processing of the task demands
(Silberstein et al., 2001). At this stage, it is unclear whether the
reduced posterior SSVEP amplitude in this window following
the cue stimuli reflects this visual processing, or a greater top-
down biasing of attention to the visual stimuli following the cue
in a manner paralleling the proposed role for alpha oscillations
in top-down control of attention (for a review, see Foxe and
Snyder, 2011). Similarly, the potential mechanism by which this
amplitude was further reduced post-MVM treatment is not fully
elucidated.
We have previously reported a single dose of MVM resulted
in frontal SSVEP amplitude reductions and phase advance, in
this period between cue and target stimuli during the A-X CPT
(White et al., 2016). Whilst not reaching criteria for significance
when controlling for multiple comparisons, the frontal SSVEP
amplitude reduction and phase advance observed in the current
Frontiers in Aging Neuroscience | www.frontiersin.org 16 December 2016 | Volume 8 | Article 288
fnagi-08-00288 December 1, 2016 Time: 17:31 # 17
White et al. Micronutrients and Brain Activity
trial was consistent with this previous acute investigation off
MVM treatment, in terms of the precise task window, the
direction of change in both SSVEP amplitude and phase, and
the spatial location of the effect. The previous study, however,
observed that this pattern of change was correlated with the
change in task performance, this was not the case in the current
study.
Behavioral Measures of Cognitive Task
Performance
Despite evidence for changes in functional brain activity,
behavioral performance on the cognitive tasks completed
during monitoring of functional brain activity did not
significantly differ between treatment groups in parallel
with these neurophysiological changes. This trial was designed
as an exploratory investigation with functional brain activity
(measured with SSVEP and fMRI) as the primary outcomes.
As such, a priori sample size determination did not power the
study to detect behavioral performance changes, nor were the
task paradigms themselves optimized for capturing behavioral
differences (rather they were operationalized primarily as
activation tasks). Studies to test cognitive benefits of MVM
supplementation in healthy adults have involved considerably
larger samples in detecting relatively subtle cognitive effects
(Haskell et al., 2010; Kennedy et al., 2010), indeed, meta-analysis
suggests a standardized mean difference for immediate recall
in the small to medium range (Grima et al., 2012), further
emphasizing the need for considerably larger sample sizes
where assessing cognitive performance changes as the primary
outcome.
An alternative strategy in assessing the functional relevance
of observed neurophysiological changes associated with MVM
treatment has been to explore the association between the
change in functional brain activity and the change in behavioral
measures of cognitive task performance. In the present study,
the greater RVIP task-related BOLD response observed after
active MVM treatment within the fatigued cohort was correlated
with performance changes. This indicates that the greater the
increase in functional brain activity post-treatment, the more
improved behavioral performance on the RVIP task. However,
while we have previously reported associations between patterns
of SSVEP response change and behavioral performance (White
et al., 2016), this relationship was not observed in the current
sample, despite trends toward faster response times on the A-X
CPT in the MVM treatment group compared to placebo. It
remains to be fully elucidated by larger scale research whether
the observed neurophysiological effects of MVM administration
represent changes of relevance to neurocognitive function which
were subthreshold given the limitations in sample size and
insensitivity of the behavioral cognitive outcomes in the present
study.
Mechanisms of MVM Supplementation in
Neurocognitive Function
The very nature of MVM supplementation complicates the
isolation of specific mechanisms by which these interventions
exert observed effects, given both the multitude of constituents
and the multitude of cellular processes in which they serve as
critical cofactors (Kennedy, 2016). Indeed, the complementary
and interactive roles these micronutrients play in such critical
cellular pathways suggest that a reductionist search to isolate
a single candidate active constituent and pathway may be
inappropriate (Kennedy (2016) for a thorough account of the
potential advantages of multiple micronutrient administration
over single nutrient preparations). Instead a more integrated
view of the multiple mechanisms impacted by MVM treatment
may be relevant. For example, the role of these micronutrients
in energy metabolism and neurotransmitter synthesis appear as
two prominent, not mutually exclusive, pathways through which
MVM supplementation may exert neurocognitive effects such as
the improved mood (White et al., 2015) and potential changes
to functional brain activity during cognitive task engagement
observed as part of the current trial.
Nonetheless, MVM formulations are not standardized in
the marketplace and greater provision of one nutrient relative
to another may contribute to the benefits obtained from
supplementation. In the current study, the levels of B vitamins
are at or above the recommended daily intakes (Table 1),
suggesting that such treatment should redress any insufficiencies
in these micronutrients (White et al., 2015). Blood markers
showed that levels of key vitamins did change in this cohort
(White et al., 2015), although the study was not powered to
relate individual differences in nutrient status to neurocognitive
or behavioral responses. Future studies may also consider
the influence of pre-existing health and nutrient status of
the individuals receiving the supplement. This is particularly
important given evidence of inadequate intakes of a range of
micronutrients associated with a Western style diet (Troesch
et al., 2012).
Beyond the theoretical biochemical pathways which link
micronutrient treatment with these mechanisms, experimental
data also supports the possibility for manipulating these
processes through micronutrient administration. Daily MVM
supplementation amongst obese adult females over 26 weeks has
been shown to result in increased resting energy expenditure,
along with reductions in fat mass, body weight and cholesterol
(Li et al., 2010). Furthermore, Kennedy et al. (2016) reported
increased energy expenditure following both acute and chronic
MVM administration in healthy younger adult females during
completion of a cognitive battery. In support of the notion
that administration of even a single B vitamin may influence
neurotransmitter synthesis, there exists research in lower
mammals demonstrating that administration of vitamin B6 leads
to an increase in central serotonin levels (Hartvig et al., 1995;
Calderon-Guzman et al., 2004).
Whilst the present work has focused on enhancing function in
healthy adults, a further pathway through which a more targeted
B vitamin supplementation scheme may exert neurocognitive
changes in at least one at-risk population warrants discussion.
Smith et al. (2010) have described a very clear candidate
mechanism by which B vitamin supplementation may exert
neurocognitive changes, reducing homocysteine as part of the
methionine cycle, in turn minimizing gray matter atrophy and
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slowing cognitive decline in older adults diagnosed with Mild
Cognitive Impairment presenting with elevated homocysteine
(de Jager et al., 2012; Douaud et al., 2013). Thus, while further
research is required to fully characterize the physiological
changes associated with MVM supplementation in both health
and disease, there is evidence to suggest energy metabolism,
neurotransmitter synthesis, as well as direct outcomes of one
carbon transfer cycles such as reduced homocysteine, are
mechanisms modifiable by micronutrient administration.
CONCLUSION
An emerging focus on optimal micronutrient intake, beyond
that required to avoid clinical deficiency, questions whether
otherwise healthy individuals may gain benefit from MVM
supplementation. Whilst some research supports benefits to
mood and possibly cognitive function, research exploring parallel
physiological changes is also underway. Outcomes of the present
trial provide evidence to suggest potential changes in functional
brain activity following 4 weeks MVM supplementation
using both hemodynamic and electrophysiological measures.
In particular, converging evidence from fMRI and SSVEP
recordings showed patterns of brain activity consistent with
greater activity in overlapping centro-parietal regions following
MVM administration during working memory. The fMRI
findings were, however, only observed amongst the subset of
participants undergoing this assessment under fatigue. Evidence
of SSVEP changes during a cued attention task were also
observed, partially consistent with a previous report after a
single dose (White et al., 2016), however, these changes were
not associated with behavioral performance on the task. All
of the observed changes were consistent with recruitment of
additional neural resources or greater excitatory processes during
task engagement, that is, greater task-related BOLD response
and SSVEP amplitude reductions and phase advance. Thus, the
present study provides preliminary evidence to suggest daily
ingestion of a high dose B vitamin micronutrient supplement
over 4 weeks may increase task-related functional brain activity
in healthy adults. These findings are of further relevance given
that, while a healthy diet may be sufficient to maintain adequate
supplies of these essential micronutrients, dietary surveys of
countries which follow a modern Western dietary pattern
indicate a significant proportion of the population may not meet
recommendations for a range of micronutrients, including B
vitamins (Troesch et al., 2012).
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